Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

75%

6 of 8 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

3(33.3%)

Phase 1

3(33.3%)

N/A

2(22.2%)

Phase 4

1(11.1%)

9Total

Phase 2(3)

Phase 1(3)

N/A(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04827901Phase 2Completed

XEN1101 for Major Depressive Disorder

Role: lead

NCT05526430Phase 1Completed

Study of Harmine in Healthy Subjects

Role: lead

NCT03043560Phase 2Completed

Study to Treat Major Depressive Disorder With a New Medication

Role: lead

NCT01882829Phase 2Completed

Nuedexta in Treatment-Resistant Major Depression

Role: lead

NCT01507181Phase 4Completed

Ketamine For Suicidal Ideation

Role: lead

NCT01304147Not ApplicableCompleted

Intranasal Ketamine in Treatment-Resistant Depression

Role: lead

NCT01533519Phase 1Completed

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

Role: lead

NCT00548964Phase 1Completed

Continuation Ketamine in Major Depression

Role: lead

NCT01309581Not ApplicableTerminated

Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression

Role: lead

All 9 trials loaded